Levels of 5α-Reductase Type 1 and Type 2 are Increased in Localized High Grade Compared to Low Grade Prostate Cancer

Journal of Urology

Volumn 179, Issue 1, 2008, Pages 147-151

  Thomas, Lynn N ^a   Douglas, Robert C ^a   Lazier, Catherine B ^a   Gupta, Rekha ^b   Norman, Richard W ^b   Murphy, Paul R ^b   Rittmaster, Roger S ^b,c   Too, Catherine K L ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c GLAXOSMITHKLINE   (United States)

Author keywords

dihydrotestosterone; dutasteride; finasteride; prostate; prostatic neoplasms

Indexed keywords

STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE 1; STEROID 5ALPHA REDUCTASE 2; STEROID-5ALPHA-REDUCTASE TYPE 1; STEROID-5ALPHA-REDUCTASE TYPE 2; UNCLASSIFIED DRUG;

AGED; ARTICLE; CANCER GRADING; CANCER LOCALIZATION; CONTROLLED STUDY; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; CHEMISTRY; COMPARATIVE STUDY; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR;

AGED; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 36749022314     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.08.155     Document Type: Article

References (20)

1. Imperato-McGinley J., Gautier T., Zirinsky K., Hom T., Palomo O., Stein E., et al. Prostate visualization studies in males homozygous and heterozygous for 5α-reductase deficiency. J Clin Endocrinol Metab 75 (1992) 1022
2. Petrow V. The dihydrotestosterone (DHT) hypothesis of prostate cancer and its therapeutic implications. Prostate 9 (1986) 343
3. Askew E.B., Gampe Jr. R.T., Stanley T.B., Faggart J.L., and Wilson E.M. Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone. J Biol Chem 282 (2007) 25801
4. Wright A.S., Douglas R.C., Thomas L.N., Lazier C.B., and Rittmaster R.S. Androgen-induced regrowth in the castrated rat ventral prostate: role of 5α-reductase. Endocrinology 140 (1999) 4509
5. Thompson I.M., Goodman P.J., Tangen C.M., Lucia M.S., Miller G.J., Ford L.G., et al. The Influence of finasteride on the development of prostate cancer. N Engl J Med 349 (2003) 213
6. Thomas L.N., Lazier C.B., Gupta R., Norman R.W., Troyer D.A., O'Brien S.P., et al. Differential alterations in 5α-reductase type 1 and type 2 levels during development and progression of prostate cancer. Prostate 63 (2005) 231
7. Span P.N., Benraad T.J., Sweep C.G., and Smals A.G. Kinetic analysis of steroid 5α-reductase activity at neutral pH in benign prostatic hyperplastic tissue: evidence for type I isozyme activity in the human prostate. J Steroid Biochem Mol Biol 57 (1996) 103
8. Clark R.V., Hermann D.J., Cunningham G.R., Wilson T.H., Morrill B.B., and Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5α-reductase inhibitor. J Clin Endocrinol Metab 89 (2004) 2179
9. Andriole G.L., Humphrey P., Ray P., Gleave M.E., Trachtenberg J., Thomas L.N., et al. Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. J Urol 172 (2004) 915
10. Span P.N., Voller M.C., Smals A.G., Sweep F.G., Schalken J.A., Feneley M.R., et al. Selectivity of finasteride as an in vivo inhibitor of 5α-reductase isozyme enzymatic activity in the human prostate. J Urol 161 (1999) 332
11. McConnell J.D., Wilson J.D., George F.W., Geller J., Pappas F., and Stoner E. Finasteride, an inhibitor of 5α-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab 74 (1992) 505
12. Iehle C., Radvanyi F., Gil Diez de Medina S., Ouafik L.H., Gerard H., Chopin D., et al. Differences in steroid 5α-reductase isoenzymes expression between normal and pathological human prostate tissue. J Steroid Biochem Mol Biol 68 (1999) 189
13. Thomas L.N., Douglas R.C., Vessey J.P., Gupta R., Fontaine D., Norman R.W., et al. 5α-Reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium. J Urol 170 (2003) 2019
14. Titus M.A., Gregory C.W., Ford III O.H., Schell M.J., Maygarden S.J., and Mohler J.L. Steroid 5α-reductase isozymes I and II in recurrent prostate cancer. Clin Cancer Res 11 (2005) 4365
15. Luo J., Dunn T.A., Ewing C.M., Walsh P.C., and Isaacs W.B. Decreased gene expression of steroid 5α-reductase 2 in human prostate cancer: implications for finasteride therapy of prostate carcinoma. Prostate 57 (2003) 134
16. Soderstrom T.G., Bjelfman C., Brekkan E., Ask B., Egevad L., Norlen B.J., et al. Messenger ribonucleic acid levels of steroid 5α-reductase 2 in human prostate predict the enzyme activity. J Clin Endocrinol Metab 86 (2001) 855
17. Xu Y., Dalrymple S.L., Becker R.E., Denmeade S.R., and Isaacs J.T. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clin Cancer Res 12 (2006) 4072
18. Akduman B., and Crawford D.E. The PCPT: new findings, new insights, and clinical implications for the prevention of prostate cancer. Eur Urol, suppl 5 (2006) 634
19. Serfling R., Shulman M., Thompson G.L., Xiao Z., Benaim E., Roehrborn C.G., et al. Quantifying the impact of prostate volumes, number of biopsy cores and 5alpha-reductase inhibitor therapy on the probability of prostate cancer detection using mathematical modeling. J Urol 177 (2007) 2352
20. Gregory C.W., Johnson Jr. R.T., Mohler J.L., French F.S., and Wilson E.M. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 61 (2001) 2892